Representative Image
NEW DELHI: A study conducted by Clinical Infectious Diseases, in collaboration with National Institute of Virology and Indian Council of Medical Research (ICMR), found that Bharat Biotech’s Covaxin produces neutralising effects against all the new COVID-19 key variants, including the double mutant strains B.1.617 and B.1.1.7.
The findings of the study state that there is no difference in neutralisation between the UK variant and the vaccine strain of D614G. Dr Harsh Vardhan, Minister of Health and Family Welfare, Government of India, also said earlier that Covaxin is likely to be effective against the UK variant and the double mutated B.1.717 variant.
Covaxin is an inactivated vaccine which is developed with the help of dead coronaviruses isolated by the National Institute of Virology. It works by teaching the immune system of the body to produce antibodies against the SARS-CoV-2. Dr VK Paul, Member, NITI Aayog, said that Bharat Biotech is ready to share its vaccine formula with other manufacturers.
Representative Image NEW DELHI: Nitin Gadkari, Minister for Road Transport and Highways, Government of India,…
Representative Image GANDHINAGAR, Gujarat: Gujarat has reached a significant milestone in the construction of homes…
Representative Image THANE, Maharashtra: The Mira Bhayander Municipal Corporation (MBMC) in Maharashtra has established a…
Representative Image NEW DELHI: With the aim to tackle the increasing air pollution level in…
Representative Image LUCKNOW, Uttar Pradesh: The Uttar Pradesh State Industrial Development Authority (UPSIDA) has come…
Representative Image NEW DELHI: The Delhi Jal Board (DJB) plans to collaborate with the Water…